-
1
-
-
79952260758
-
Improved survival prospects for patients with castration-resistant prostate cancer
-
Kirby R, Fitzpatrick JM,. Improved survival prospects for patients with castration-resistant prostate cancer. BJU Int 2011; 107: 697-700
-
(2011)
BJU Int
, vol.107
, pp. 697-700
-
-
Kirby, R.1
Fitzpatrick, J.M.2
-
2
-
-
75749098139
-
Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges
-
Glina S, Rivero MA, Morales A, Morgentaler A,. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges. J Sex Med 2010; 7: 640-4
-
(2010)
J Sex Med
, vol.7
, pp. 640-644
-
-
Glina, S.1
Rivero, M.A.2
Morales, A.3
Morgentaler, A.4
-
3
-
-
84858212484
-
Prostate-cancer mortality at 11 years of follow-up
-
Schroder FH, Hugosson J, Roobol MJ, et al,. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90
-
(2012)
N Engl J Med
, vol.366
, pp. 981-990
-
-
Schroder, F.H.1
Hugosson, J.2
Roobol, M.J.3
-
4
-
-
84859645406
-
Active surveillance for favorable-risk prostate cancer: Background, patient selection, triggers for intervention, and outcomes
-
Klotz L,. Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. Curr Opin Urol 2012; 22: 222-30
-
(2012)
Curr Opin Urol
, vol.22
, pp. 222-230
-
-
Klotz, L.1
-
5
-
-
84862877628
-
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial
-
Vickers A, Bennette C, Steineck G, et al,. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial. Eur Urol 2012; 62: 204-9
-
(2012)
Eur Urol
, vol.62
, pp. 204-209
-
-
Vickers, A.1
Bennette, C.2
Steineck, G.3
-
7
-
-
78650257452
-
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: A critical review of outcomes reported by high-volume centers
-
Coelho RF, Rocco B, Patel MB, et al,. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol 2010; 24: 2003-15
-
(2010)
J Endourol
, vol.24
, pp. 2003-2015
-
-
Coelho, R.F.1
Rocco, B.2
Patel, M.B.3
-
8
-
-
84861576924
-
Focal therapy for localised unifocal and multifocal prostate cancer: A prospective development study
-
Ahmed H, Hindley R, Dickinson L, et al,. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13: 622-32
-
(2012)
Lancet Oncol
, vol.13
, pp. 622-632
-
-
Ahmed, H.1
Hindley, R.2
Dickinson, L.3
-
9
-
-
67650602865
-
High intensity focused ultrasound - Early experience and 2 year results
-
Challacombe B, Zakri R, Murphy D, Cahill D,. High intensity focused ultrasound-early experience and 2 year results. BJU Int 2009; 104: 200-4
-
(2009)
BJU Int
, vol.104
, pp. 200-204
-
-
Challacombe, B.1
Zakri, R.2
Murphy, D.3
Cahill, D.4
-
10
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
DOI 10.1056/NEJMoa040720
-
Tannock IF, de Wit R, Berry WR, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Theodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
11
-
-
38349167518
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
-
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5
-
(2008)
J Clin Oncol
, vol.26
, pp. 242-245
-
-
Berthold, D.R.1
Pond, G.R.2
Soban, F.3
De Wit, R.4
Eisenberger, M.5
Tannock, I.F.6
-
12
-
-
33646443546
-
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
-
DOI 10.1093/jnci/djj129
-
Petrylak DP, Ankerst DP, Jiang CS, et al,. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-21 (Pubitemid 43898814)
-
(2006)
Journal of the National Cancer Institute
, vol.98
, Issue.8
, pp. 516-521
-
-
Petrylak, D.P.1
Ankerst, D.P.2
Jiang, C.S.3
Tangen, C.M.4
Hussain, M.H.A.5
Lara Jr., P.N.6
Jones, J.A.7
Taplin, M.E.8
Burch, P.A.9
Kohli, M.10
Benson, M.C.11
Small, E.J.12
Raghavan, D.13
Crawford, E.D.14
-
13
-
-
77956542827
-
Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)
-
(Suppl.)
-
De Bono JS, Oudard S, Ozguroglu M, et al,. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J Clin Oncol 2010; 28 (Suppl.): 4508
-
(2010)
J Clin Oncol
, vol.28
, pp. 4508
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
14
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
-
de Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
-
(2010)
Lancet
, vol.376
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
15
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
de Bono JS, Logothetis CJ, Molina A, et al,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
-
(2011)
N Engl J Med
, vol.364
, pp. 1995-2005
-
-
De Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
16
-
-
84865336863
-
Optimizing the care of patients with advanced prostate cancer in the UK: Current challenges and future opportunities
-
[Epub ahead of print]. DOI: 10.1111/j.1464-410X.2011.10886.x
-
Payne H, Bahl A, Mason M, Troup J, De Bono J,. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; [Epub ahead of print]. DOI: 10.1111/j.1464-410X. 2011.10886.x
-
(2012)
BJU Int
-
-
Payne, H.1
Bahl, A.2
Mason, M.3
Troup, J.4
De Bono, J.5
-
17
-
-
77952105685
-
Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
-
Scher HI, Beer TM, Higano CS, et al,. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46
-
(2010)
Lancet
, vol.375
, pp. 1437-1446
-
-
Scher, H.I.1
Beer, T.M.2
Higano, C.S.3
-
18
-
-
33746012881
-
Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
-
DOI 10.1200/JCO.2005.04.5252
-
Small EJ, Schellhammer PF, Higano CS, et al,. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94 (Pubitemid 46638945)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.19
, pp. 3089-3094
-
-
Small, E.J.1
Schellhammer, P.F.2
Higano, C.S.3
Redfern, C.H.4
Nemunaitis, J.J.5
Valone, F.H.6
Verjee, S.S.7
Jones, L.A.8
Hershberg, R.M.9
-
19
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff P, Higano C, Shore D, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-21
-
(2010)
N Engl J Med
, vol.363
, pp. 411-421
-
-
Kantoff, P.1
Higano, C.2
Shore, D.3
|